Martin Comberbach appointed as Director of GMP Manufacturing Operations, Paul Stockbridge appointed Director of Quality and Tony Mulcahy promoted to Director of Customer Relations.
Cobra Biomanufacturing Plc (London Stock Exchange AIM) announced that it has strengthened its senior management team.
Martin Comberbach PhD, Director of GMP Manufacturing Operations, comes from a pharmaceutical process and project engineering background having held senior positions at GSK’s Rixensart vaccine facility, Metris Therapeutics Ltd, and more recently as Director of Global Manufacturing for GeneMedix Plc.
Paul Stockbridge PhD, Director of Quality, has over 25 years experience in the pharmaceutical / biotechnology industry. After 23 years with Eli Lilly in the UK he moved to Aventis Pharma in 2002 where he was Head of Quality Operations at their Holmes Chapel (UK) site. He is registered as a Qualified Person under the Permanent Provisions of the EU directives, bringing our number of QPs to three, and is highly experienced in interacting with many inspectional bodies including the FDA and the MHRA.
Following 12 years with Cobra, most recently as European Director of Business Development, Tony Mulcahy PhD has been promoted to the new role of Director of Customer Relations with global responsibility for contract management and marketing functions.
Dr David Thatcher, CEO of Cobra commented,
“We are delighted that Paul and Martin have joined Cobra to further strengthen our GMP production services. Together with Tony’s promotion, this demonstrates Cobra’s total commitment to quality and customer service as key drivers of our business. Since listing on AIM in 2002 Cobra has established itself as a global leader in biopharmaceuticals manufacture. These appointments add considerable strength to our senior management team as we prepare for our next phase of growth.”
- ENDS -